Clarivate Epidemiology's coverage of allergic rhinitis (AR) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of AR for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology's AR forecast will answer the following questions:
Of all people with AR, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
Of all people diagnosed with AR, how many in each country across the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AR over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts nine AR patient populations, as follows:
Prevalence of Allergic Rhinitis per 1,000 People of All Ages in 2021 and 2041
Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Allergic Rhinitis Over the Next 20 Years
Analysis of the Prevalent Cases of Allergic Rhinitis by Diagnosed and Drug-Treated Status
Analysis of the Prevalent Cases of Allergic Rhinitis by Symptom Duration
Analysis of the Prevalent Cases of Allergic Rhinitis by Symptom Severity
Epidemiology Data
Methods
Total Prevalent Cases
Total Prevalence by Symptom Duration
Total Prevalence by Symptom Severity
Diagnosed Prevalent Cases
Drug-Treated Prevalent Cases
Reference Materials
Literature Review
Studies Included in the Analysis of Allergic Rhinitis
Studies Excluded from the Analysis of Allergic Rhinitis
Risk / Protective Factors
Risk / Protective Factors for Allergic Rhinitis
Bibliography
Abbreviations
Glossary
Soundharya M
Soundharya M, M.P.H., is an associate epidemiologist at Clarivate. Prior to joining the company, she worked as a project coordinator at an NGO. She holds a master’s degree in public health with a specialization in epidemiology from the Manipal Academy of Higher Education. Her area of interest is chronic disease epidemiology.
Shilpa Thakur
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.
